Supplementary Figure S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1 | Synapse
October 17, 2025Open Access
Supplementary Figure S2 from Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2− Advanced Breast Cancer: Results from SERENA-1
Puntos clave
Heart rate reductions were significant among patients receiving treatment, highlighting the need for careful monitoring.
QTcF prolongation was documented in a portion of the subjects, suggesting potential cardiac implications.
Combining camizestrant with CDK4/6 inhibitors showed promising therapeutic outcomes, warranting further investigation.
The study sample consisted of women diagnosed with advanced breast cancer, emphasizing the relevance of findings.